@article{article, title  = {{DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2020}},

 month = {{2}},

 author = {{Niazi T and Williams S and Davis ID and Stockler MR and Martin AJ and Hague W and Bracken K and Gorzeman M and Roncolato F and Yip S and Horvath L et al}},

 doi = {{10.1200/jco.2020.38.6_suppl.tps385}},

 volume = {{38}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{TPS385-TPS385}},

 note = {{Accessed on 2024/12/22}}}